☆ 4.6 Meeting Abstract

ASSESSING THE COST-EFFECTIVENESS OF THE NOVAVAX COVID-19 VACCINE AS A POTENTIAL BOOSTER VACCINE OPTION FOR ADULTS IN THE UNITED STATES

VALUE IN HEALTH (2022)

Journal

VALUE IN HEALTH

Volume 25, Issue 12, Pages S89-S89

Publisher

ELSEVIER SCIENCE INC

Keywords

-

Categories

Economics Health Care Sciences & Services Health Policy & Services

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Authors

I am an author on this paper

Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6

Not enough ratings

Secondary Ratings

Novelty

-

Significance

-

Scientific rigor

-

Rate this paper

Recommended

No Data Available

No Data Available

No Data Available

© Peeref 2019-2024. All rights reserved.